Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03354611 · ClinicalTrials.gov registry record · Phase 2

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

A Phase 2 study, sponsored by Koning Corporation.

Terminated
Registry status
Phase 2
Development phase
21
Enrollment target

NCT03354611: Clinical Trial Phase 2 study, sponsored by Koning Corporation.

NCT03354611 is a Phase 2 study that was terminated before completion, run by Koning Corporation. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03354611, a Phase 2 study, was terminated before completion, sponsored by Koning Corporation.

TERMINATED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammography and before breast biopsy if biopsy is needed. The final diagnostic workup outcome of these enrolled patients needs to include at least 30 confirmed cancers cases.

Interventions

  • RADIATION Contrast Enhanced Cone Beam Breast CT Scan
  • DRUG Contrast Dye, Iodinated

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2018-09-10
Est. Completion 2021-09-01
Phase Phase 2

Sponsor

Koning Corporation

7 total trials

What the Registry Record Tells You About NCT03354611

The ClinicalTrials.gov registry entry for NCT03354611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Koning Corporation, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Contrast Enhanced Cone Beam Breast CT Scan is the first listed.

NCT03354611 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03354611 about?

NCT03354611 is a clinical study titled "Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging". Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammo...

What is the current status of trial NCT03354611?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-09-10. Estimated completion is 2021-09-01.

What interventions are being tested in trial NCT03354611?

The interventions under investigation include: Contrast Enhanced Cone Beam Breast CT Scan (RADIATION), Contrast Dye, Iodinated (DRUG).

Who is sponsoring clinical trial NCT03354611?

This trial is sponsored by Koning Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.